NSE - Delayed Quote INR

Aurobindo Pharma Limited (AUROPHARMA.NS)

Compare
1,176.35
+18.50
+(1.60%)
At close: 3:29:59 PM GMT+5:30
Loading Chart for AUROPHARMA.NS
  • Previous Close 1,157.85
  • Open 1,229.00
  • Bid --
  • Ask --
  • Day's Range 1,173.05 - 1,267.30
  • 52 Week Range 1,031.05 - 1,592.00
  • Volume 7,500,989
  • Avg. Volume 905,389
  • Market Cap (intraday) 683.226B
  • Beta (5Y Monthly) 0.54
  • PE Ratio (TTM) 19.65
  • EPS (TTM) 59.86
  • Earnings Date May 23, 2025 - May 27, 2025
  • Forward Dividend & Yield 4.50 (0.40%)
  • Ex-Dividend Date Feb 20, 2024
  • 1y Target Est 1,483.14

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

www.aurobindo.com

26,015

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AUROPHARMA.NS

View More

Performance Overview: AUROPHARMA.NS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

AUROPHARMA.NS
11.85%
S&P BSE SENSEX (^BSESN)
2.36%

1-Year Return

AUROPHARMA.NS
3.40%
S&P BSE SENSEX (^BSESN)
3.27%

3-Year Return

AUROPHARMA.NS
75.75%
S&P BSE SENSEX (^BSESN)
28.71%

5-Year Return

AUROPHARMA.NS
217.14%
S&P BSE SENSEX (^BSESN)
176.52%

Compare To: AUROPHARMA.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AUROPHARMA.NS

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    672.48B

  • Enterprise Value

    681.53B

  • Trailing P/E

    19.36

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.22

  • Price/Book (mrq)

    2.18

  • Enterprise Value/Revenue

    2.24

  • Enterprise Value/EBITDA

    9.88

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.29%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    309.22B

  • Net Income Avi to Common (ttm)

    34.91B

  • Diluted EPS (ttm)

    59.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    68.68B

  • Total Debt/Equity (mrq)

    27.29%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: AUROPHARMA.NS

View More

Company Insights: AUROPHARMA.NS

Research Reports: AUROPHARMA.NS

View More

People Also Watch